Fifth Eye
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Fifth Eye was an Ann Arbor, Michigan-based medical device software startup, a spinout from the University of Michigan founded in 2017 and led by CEO Jen Baird. It built clinical early-warning systems for hospitals: real-time analytics that interpret a single existing electrocardiogram (ECG) waveform — using machine learning — to detect hemodynamic instability (when blood flow to vital organs degrades) before patients show distress, warning of impending low blood pressure, cardiac arrest, or heart failure. It raised $2.4 million in seed funding (2018) from Invest Michigan and 35 investors, then an $11.5 million Series A (2019) led by Arboretum Ventures and Cultivation Capital, with the University of Michigan endowment's MINTS participating, to secure FDA clearance of its first product, the Analytic for Hemodynamic Instability (AHI).
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Fifth Eye was founded in 2017 in Ann Arbor as a University of Michigan spinout, based on research from the Center for Integrative Research in Critical Care (MCIRCC).
- Seed
The company raised $2.4 million in seed funding led by Invest Michigan, with its system in testing on 200 hospital beds at Michigan Medicine.
- Series A
Fifth Eye raised an $11.5 million Series A led by Arboretum Ventures and Cultivation Capital to secure FDA clearance of its first product and begin human trials at Michigan hospitals.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.